Kintara Therapeutics Announces Special Meeting for TuHURA Merger - TipRanks

KTRADelisted Stock  USD 6.30  0.14  2.17%   
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Kintara Therapeutics Announces Special Meeting for TuHURA Merger TipRanks

Read at news.google.com
Google News at Macroaxis
  

Kintara Therapeutics Fundamental Analysis

We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

Kintara Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Kintara Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.

Peers

Kintara Therapeutics Related Equities

ONCYOncolytics Biotech   1.85   
0%
10.0%
MCRBSeres Therapeutics   1.59   
0%
8.0%
SCPHScpharmaceuticals   0.31   
0%
1.0%
LUMOLumos Pharma   0.23   
0%
1.0%
SLRXSalarius Pharmaceuticals   0.00   
0%
0%
MISTMilestone Pharmaceuticals   0.00   
0%
0%
LSTALisata Therapeutics   0.00   
0%
0%
TOVXTheriva Biologics   0.85   
4.0%
0%
CLRBCellectar Biosciences   0.88   
4.0%
0%
VCNXVaccinex   1.08   
5.0%
0%
DMACDiaMedica Therapeutics   1.30   
7.0%
0%
GOVXGeoVax Labs   2.55   
14.0%
0%
BOLTBolt Biotherapeutics   2.83   
15.0%
0%
SABSSAB Biotherapeutics   2.94   
16.0%
0%
DYAIDyadic International   8.59   
47.0%
0%
FBRXForte Biosciences   18.10   
100.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance